| Mrs Diana Elaine Ballard, | |
|
9071 S 1300 W Ste 210, West Jordan, UT 84088-6725 | |
| (801) 833-1291 | |
| Not Available |
| Full Name | Mrs Diana Elaine Ballard |
|---|---|
| Gender | Female |
| Speciality | Social Worker - Clinical |
| Location | 9071 S 1300 W Ste 210, West Jordan, Utah |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1235531641 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 1041C0700X | Social Worker - Clinical | 9490518-3501 (Utah) | Primary |
| Entity Name | Compass Counseling And Consulting |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1356669360 PECOS PAC ID: 0042525990 Enrollment ID: O20150820011996 |
News Archive
Vanda Pharmaceuticals Inc. announced today that the European Medicines Agency (EMA) accepted for evaluation Vanda's Marketing Authorization Application (MAA) for oral iloperidone tablets.
The PREVENTOMICS European project will develop, from this November and for 3 years, personalized plans for nutrition and lifestyle habits to improve the health of people, based on individual traits such as physical and behavioral traits, lifestyle, genotype, preferences and physical condition.
Avila Therapeutics, Inc., a biotechnology company developing novel covalent drugs that treat diseases through protein silencing, presented results of preclinical studies on its highly selective, pan-genotype, small molecule Hepatitis C Virus (HCV) protease inhibitor, AVL-181.
Led by the University of Sydney researchers and published today in The Lancet Child & Adolescent Health, this is the first population-based cohort study to assess both adult fertility and cancer risk after surgical correction (orchidopexy) for undescended testes in early childhood.
› Verified 7 days ago
| Entity Name | River Oak Counseling Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1629677364 PECOS PAC ID: 0345695953 Enrollment ID: O20231017000051 |
News Archive
Vanda Pharmaceuticals Inc. announced today that the European Medicines Agency (EMA) accepted for evaluation Vanda's Marketing Authorization Application (MAA) for oral iloperidone tablets.
The PREVENTOMICS European project will develop, from this November and for 3 years, personalized plans for nutrition and lifestyle habits to improve the health of people, based on individual traits such as physical and behavioral traits, lifestyle, genotype, preferences and physical condition.
Avila Therapeutics, Inc., a biotechnology company developing novel covalent drugs that treat diseases through protein silencing, presented results of preclinical studies on its highly selective, pan-genotype, small molecule Hepatitis C Virus (HCV) protease inhibitor, AVL-181.
Led by the University of Sydney researchers and published today in The Lancet Child & Adolescent Health, this is the first population-based cohort study to assess both adult fertility and cancer risk after surgical correction (orchidopexy) for undescended testes in early childhood.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mrs Diana Elaine Ballard, 1368 W Green Hedge Way, West Jordan, UT 84084-4140 Ph: (801) 833-1291 | Mrs Diana Elaine Ballard, 9071 S 1300 W Ste 210, West Jordan, UT 84088-6725 Ph: (801) 833-1291 |
News Archive
Vanda Pharmaceuticals Inc. announced today that the European Medicines Agency (EMA) accepted for evaluation Vanda's Marketing Authorization Application (MAA) for oral iloperidone tablets.
The PREVENTOMICS European project will develop, from this November and for 3 years, personalized plans for nutrition and lifestyle habits to improve the health of people, based on individual traits such as physical and behavioral traits, lifestyle, genotype, preferences and physical condition.
Avila Therapeutics, Inc., a biotechnology company developing novel covalent drugs that treat diseases through protein silencing, presented results of preclinical studies on its highly selective, pan-genotype, small molecule Hepatitis C Virus (HCV) protease inhibitor, AVL-181.
Led by the University of Sydney researchers and published today in The Lancet Child & Adolescent Health, this is the first population-based cohort study to assess both adult fertility and cancer risk after surgical correction (orchidopexy) for undescended testes in early childhood.
› Verified 7 days ago
Susannah Holden, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 4983 W Amethyst Dr, West Jordan, UT 84081 Phone: 801-660-7194 | |
Mr. Spencer Giles Morgan, MSW LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 9253 B Redwood Rd, West Jordan, UT 84088 Phone: 801-566-4079 | |
Chelsey Tautkus, Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 7601 South Redwood Road,, Building E, West Jordan, UT 84084 Phone: 801-233-8670 Fax: 801-233-8682 | |
Jessie Ann Ritchey, APRN Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 7181 S Campus View Dr Ste 1a, West Jordan, UT 84084 Phone: 801-613-9843 | |
Janaka Vander Kooi, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 9263 Redwood Rd Bldg 8, West Jordan, UT 84088 Phone: 801-566-0749 Fax: 801-566-7108 | |
David Burrows, LCSW Clinical Social Worker Medicare: Medicare Enrolled Practice Location: 8783 S Redwood Rd Ste C, West Jordan, UT 84088 Phone: 435-799-5035 Fax: 435-535-3782 | |
Carolyn Memmott, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 8537 S Redwood Rd Ste C2, West Jordan, UT 84088 Phone: 801-829-9726 |